Acute lymphocytic leukaemia recurrent
Not recruitingStudy on Tisagenlecleucel for High-Risk B-Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients with Minimal Residual Disease
Study on Tisagenlecleucel for High-Risk B-Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients with Minimal Residual Disease
- Disease:Acute lymphocytic leukaemia recurrent
- Substances:Tisagenlecleucel
Italy- Participants:0–17 years · 18–64 years
- Substances:Tisagenlecleucel
- Sponsor:Novartis Pharma AG











